Latest news for Corix Bioscience (OTC:CXBS) Stock

Corix Bioscience Inc is a United States-based research and development firm of cannabidiol (CBD) products and treatments. It is engaged in the business of producing organic CBD oil used for medical applications and treatments. In addition, the group is also focused on the production of tetrahydrocannabivarin oil. The company is focused on operations in Oregon, California, and Nevada, United States.

CORIX BIOSCIENCE INC by Corix Bioscience, Inc.

Corix Bioscience Inc

The European Commission (EC), which has the authority to approve medicines for the European Union (EU), will now review the CHMP recommendation.

News

Bristol Myers Squibb Gets Positive CHMP Opinion For CAR T Cell Therapy Breyanzi For Relapsed Or Refractory Follicular Lymphoma

The earnings results for TDK (OTC:<a class="ticker" href="https://www.benzinga.com/stock/TTDKY#OTC">TTDKY</a>) for Q3 were made public on Friday, January 31, 2025 at 03:00 AM.
Here's a comprehensive overview of the announcement.
<h3>Earnings</h3>
TDK beat estimated earnings by 6.0%, reporting an EPS of $0.19 versus an estimate of $0.18.
Revenue was up $29.00 million from the same period last year.
<h3>Historical Earnings Summary</h3>
Last quarter the company beat on EPS by $0.17 which was followed by a 4.0% increase in the share price the next day.
Here's a look at TDK's past performance:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q2 2025</th>
<th>Q1 2025</th>
<th>Q4 2024</th>
<th>Q3 2024</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>0.20</td>
<td>0.10</td>
<td>0.04</td>
<td>0.15</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>0.37</td>
<td>0.22</td>
<td>0.02</td>
<td>0.23</td>
</tr>
<tr>
<td>Revenue Estimate</td>
<td>3.98B</td>
<td>3.19B</td>
<td>3.23B</td>
<td>3.84B</td>
</tr>
<tr>
<td>Revenue Actual</td>
<td>3.83B</td>
<td>3.33B</td>
<td>3.27B</td>
<td>3.79B</td>
</tr>
</tbody>
</table>

To track all earnings releases for TDK <a href="https://www.benzinga.com/quote/TTDKY/earnings">visit their earnings calendar here.</a> 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Earnings

TTDKY

Earnings Breakdown: TDK Q3

The&nbsp;&nbsp;&nbsp;&nbsp;Company&nbsp;&nbsp;&nbsp;&nbsp;declared&nbsp;&nbsp;&nbsp;&nbsp;a&nbsp;&nbsp;&nbsp;&nbsp;regular&nbsp;&nbsp;&nbsp;&nbsp;quarterly&nbsp;&nbsp;&nbsp;&nbsp;dividend&nbsp;&nbsp;&nbsp;&nbsp;of&nbsp;&nbsp;&nbsp;&nbsp;$0.55&nbsp;&nbsp;&nbsp;&nbsp;per&nbsp;&nbsp;&nbsp;&nbsp;share,&nbsp;&nbsp;&nbsp;&nbsp;an&nbsp;&nbsp;&nbsp;&nbsp;increase&nbsp;&nbsp;&nbsp;&nbsp;of&nbsp;&nbsp;&nbsp;&nbsp;7.8&nbsp;&nbsp;&nbsp;&nbsp;percent,&nbsp;&nbsp;&nbsp;&nbsp;which&nbsp;&nbsp;&nbsp;&nbsp;is&nbsp;&nbsp;&nbsp;&nbsp;payable&nbsp;&nbsp;&nbsp;&nbsp;on&nbsp;&nbsp;&nbsp;&nbsp;March&nbsp;&nbsp;&nbsp;&nbsp;4,&nbsp;&nbsp;&nbsp;&nbsp;2025&nbsp;&nbsp;&nbsp;&nbsp;to&nbsp;&nbsp;&nbsp;&nbsp;stockholders&nbsp;&nbsp;&nbsp;&nbsp;of&nbsp;&nbsp;&nbsp;&nbsp;record&nbsp;&nbsp;&nbsp;&nbsp;on&nbsp;&nbsp;&nbsp;&nbsp;February&nbsp;&nbsp;&nbsp;&nbsp;14,&nbsp;&nbsp;&nbsp;&nbsp;2025.&nbsp;&nbsp;&nbsp;&nbsp;

Dividends

Booz Allen Hamilton Declared A QUarterly Dividend Per Share Of $0.55, Up By 7.8%

Brookfield Bus Partners (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BBU#NYSE">BBU</a>) reported $7.427 billion in sales this quarter. This is a 44.60 percent decrease over sales of $13.405 billion the same period last year.

Brookfield Bus Partners Q4 Sales $7.427B Down From $13.405B YoY

Needham analyst Ryan Koontz maintains Calix (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CALX#NYSE">CALX</a>) with a Buy and raises the price target from $45 to $53.

Price Target

Analyst Ratings

CALX

Needham Maintains Buy on Calix, Raises Price Target to $53

Needham analyst Quinn Bolton reiterates Allegro Microsystems (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALGM#NASDAQ">ALGM</a>) with a Buy and maintains $30 price target.

Reiteration

ALGM

Needham Reiterates Buy on Allegro Microsystems, Maintains $30 Price Target

Earnings Beats

Booz Allen Hamilton Q3 2025 Adj. EPS $1.55 Beats $1.51 Estimate, Sales $2.917B Beat $2.864B Estimate

Merck Says Committee For Medicinal Products For Human Use Of The European Medicines Agency Recommended The Approval Of CAPVAXIVE For Active Immunization Of Invasive Disease And Pneumonia Caused By Streptococcus Pneumoniae

TDK (OTC:<a class="ticker" href="https://www.benzinga.com/stock/TTDKY#OTC">TTDKY</a>) reported its Q3 earnings results on Friday, January 31, 2025 at 03:00 AM.
Here's what investors need to know about the announcement.
<h3>Earnings</h3>
TDK beat estimated earnings by 6.0%, reporting an EPS of $0.19 versus an estimate of $0.18.
Revenue was up $29.00 million from the same period last year.
<h3>Overview of Past Earnings</h3>
Last quarter the company beat on EPS by $0.17 which was followed by a 4.0% increase in the share price the next day.
Here's a look at TDK's past performance:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q2 2025</th>
<th>Q1 2025</th>
<th>Q4 2024</th>
<th>Q3 2024</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>0.20</td>
<td>0.10</td>
<td>0.04</td>
<td>0.15</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>0.37</td>
<td>0.22</td>
<td>0.02</td>
<td>0.23</td>
</tr>
<tr>
<td>Revenue Estimate</td>
<td>3.98B</td>
<td>3.19B</td>
<td>3.23B</td>
<td>3.84B</td>
</tr>
<tr>
<td>Revenue Actual</td>
<td>3.83B</td>
<td>3.33B</td>
<td>3.27B</td>
<td>3.79B</td>
</tr>
</tbody>
</table>

To track all earnings releases for TDK <a href="https://www.benzinga.com/quote/TTDKY/earnings">visit their earnings calendar here.</a> 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

TDK Q3 Earnings Assessment

Evercore ISI Group analyst James Kammert initiates coverage on NNN REIT (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NNN#NYSE">NNN</a>) with a In-Line rating and announces Price Target of $42.

Initiation

Evercore ISI Group Initiates Coverage On NNN REIT with In-Line Rating, Announces Price Target of $42

Fujitsu (OTC:<a class="ticker" href="https://www.benzinga.com/stock/FJTSY#OTC">FJTSY</a>) lowers FY2024 GAAP EPS guidance from $0.77 to $0.76. Lowers FY2024 sales outlook from $25.26 billion to $22.78 billion.

Guidance

FJTSY

Fujitsu Lowers FY2024 GAAP EPS Guidance from $0.77 to $0.76; Lowers FY2024 Sales Guidance from $25.26B to $22.78B

WIIM

Signing Day Sports shares are trading higher after the company announced it retains rights as the National Recruiting Partner to the U.S. Army Bowl through 2026 in new deal.

Fujitsu (OTC:<a class="ticker" href="https://www.benzinga.com/stock/FJTSY#OTC">FJTSY</a>) lowers FY2024 Adj EPS guidance from $0.82 to $0.81. sees Adj sales of $22.784 billion.

Fujitsu Lowers FY2024 Adj EPS Guidance from $0.82 to $0.81; Sees Adj Sales $22.784B

B of A Securities analyst Jessica Reif Cohen downgrades Comcast (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CMCSA#NASDAQ">CMCSA</a>) from Buy to Neutral and lowers the price target from $50 to $38.

Downgrades

CMCSA

B of A Securities Downgrades Comcast to Neutral, Lowers Price Target to $38

Signing Day Sports Announced The Signing Of A New Sponsorship Agreement With The US Army Bowl  Through 2026, Extending Its Rights As "National Recruiting Partner"

Fujitsu (OTC:<a class="ticker" href="https://www.benzinga.com/stock/FJTSY#OTC">FJTSY</a>) reported quarterly earnings of $0.04 per share. This is a 200 percent increase over losses of $(0.04) per share from the same period last year. The company reported $6.07 billion in sales this quarter. This is a 3.63 percent decrease over sales of $6.30 billion the same period last year.

Fujitsu Q3 EPS $0.04 Up From $(0.04) YoY, Sales $6.07B Down From $6.30B YoY

U.S. stock futures climbed on Friday, pointing to a third straight week of gains fueled by strong corporate earnings. Futures were higher for all four major indices.
The dollar index strengthened after Donald Trump announced Thursday that the U.S. will implement a 25% tariff on imports from Canada and Mexico, effective Saturday, Feb. 1. He also threatened the <a href="https://www.benzinga.com/government/regulations/25/01/43377987/after-imposing-tariffs-on-canada-donald-trump-threatens-100-levy-on-brics-for-move-against-dollar-how-will-us-manage-production-from-slippers-to-ships-asks-expert">BRICS nations</a> to impose 100% tariffs if they issue BRICS reserve currency.
Investors await the Personal Consumption Expenditure data for December, which will be released before the market opens.
The 10-year Treasury yield is currently at 4.53%, and the two-year yield is at 4.21%. The CME Group&#8217;s FedWatch <a href="https://www.cmegroup.com/markets/interest-rates/cme-fedwatch-tool.htm">tool </a>indicates an 82% probability that the Federal Open Market Committee will maintain current interest rates in March 2025.
<figure class="wp-block-table is-style-stripes"> 
<table>
<tbody>
<tr>
<td>Futures</td>
<td>Change (+/-)</td>
</tr>
<tr>
<td>Nasdaq 100</td>
<td>0.78%</td>
</tr>
<tr>
<td>S&amp;P 500</td>
<td>0.45%</td>
</tr>
<tr>
<td>Dow Jones</td>
<td>0.34%</td>
</tr>
<tr>
<td>Russell 2000</td>
<td>0.01%</td>
</tr>
</tbody>
</table>
</figure>
In premarket trading on Friday, both the SPDR S&amp;P 500 ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) and the Invesco QQQ Trust ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>) were higher. SPY was up 0.42% at $607.59, and QQQ gained 0.80% to reach $527.22, based on <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a> data.
Cues From The Last Session
Stocks rallied Thursday following mixed reactions to a wave of earnings reports and economic data.
This followed Wednesday&#8217;s down session after the Fed held rates steady. Investor sentiment fluctuated due to DeepSeek&#8217;s low-cost AI model launch and Big Tech earnings, this week.
Apple Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>) shares fell 0.74% despite beating first-quarter revenue and earnings estimates as iPhone sales slipped in 2024 to $69.14 billion, versus $69.7 billion last year. Revenue reached $124.3 billion as compared to $124.13 billion expected by Benzinga Pro, and adjusted earnings per share was $2.40 as compared to the expectation of $2.36 per share.
IBM Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IBM#NYSE">IBM</a>) surged nearly 13% on artificial intelligence growth, Meta Platforms Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/META#NASDAQ">META</a>) gained 1.6% on strong results, while Microsoft Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSFT#NASDAQ">MSFT</a>) fell 6.2% despite exceeding expectations due to weaker cloud revenue.
On the economic front, Q4 GDP growth and jobless claims were slightly below forecasts, but overall economic indicators remain strong, with the Fed, on Wednesday, citing a robust labor market and &#8220;somewhat elevated&#8221; inflation.
<figure class="wp-block-table is-style-stripes"> 
<table>
<tbody>
<tr>
<td>Index</td>
<td>Performance (+/-)</td>
<td>Value</td>
</tr>
<tr>
<td>Nasdaq Composite</td>
<td>0.25%</td>
<td>19,681.75</td>
</tr>
<tr>
<td>S&amp;P 500</td>
<td>0.53%</td>
<td>6,071.17</td>
</tr>
<tr>
<td>Dow Jones</td>
<td>0.38%</td>
<td>44,882.13</td>
</tr>
<tr>
<td>Russell 2000</td>
<td>1.07%</td>
<td>2,307.45</td>
</tr>
</tbody>
</table>
</figure>
Insights From Analysts
According to the analysts at BlackRock, strong corporate earnings have set the tone for the fourth-quarter season in swing.
&#8220;Even with higher-for-longer interest rates, we think U.S. stocks can keep outperforming this year. We stay overweight. Resilient economic growth is helping sectors beyond tech. That's partly driven by artificial intelligence (AI) spurring earnings beyond the initial winners during an economic transformation and policy change, we think. Yet we eye risks to risk appetite changing this year depending on earnings and policy.&#8221;
With interest rates in focus Ed Yardeni and Eric Wallerstein of Yradeni Research, said in their QuickTakes note that Fed Chair Jerome Powell&#8217;s basic message during his press conference was that the Fed is in no hurry to lower interest rates, but the Fed still intends to lower them over time.
Hence, they described it as a &#8220;dovish pause&#8221;.
Approaching the week from a technical perspective Jeff Buchbinder, the chief equity strategist at LPL Financial said that the S&amp;P 500 remains near record-high territory amid improving market breadth and momentum. &#8220;Technical damage within the heavy-weight tech sector has been minimal as buyers stepped up near support from the mid-January lows.&#8221;
Despite Monday's pullback, sector breadth is also holding up relatively well, with the majority of tech stocks trading above their 200-day moving average, Buchbinder added.
&#8220;However, technical damage has been more pronounced on a relative basis, as the tech sector vs. S&amp;P 500 ratio chart recently dropped to multi-month lows,&#8221; he said.
See Also:&nbsp;<a href="https://www.benzinga.com/money/how-to-trade-futures">How to Trade Futures</a>
Upcoming Economic Data
Here&#8217;s what investors will keep an eye on Friday:
<ul>
<li>Fed Governor Michelle Bowman will be speaking at 8:30 a.m., ET.</li>
</ul>
<ul>
<li>Employment cost index data for Q4 will be released at 8:30 a.m., ET.</li>
</ul>
<ul>
<li>Also, the core and headline personal consumption expenditure, along with personal income and spending data will be announced at 8:30 a.m., ET.</li>
</ul>
<ul>
<li>The Chicago Business Barometer (PMI) for January will be out by 9:45 a.m., ET.</li>
</ul>
Stocks In Focus:
<ul>
<li>Apple Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>) was up 3.46% in the premarket on Friday after beating the fourth-quarter expectations on Tuesday, despite a slip in iPhone sales.</li>
</ul>
<ul>
<li>Colgate-Palmolive Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CL#NYSE">CL</a>) was up 0.03% as Wall Street expects it to report earnings of 89 cents per share on revenue of $4.99 billion, before the opening bell.</li>
</ul>
<ul>
<li>Phillips 66 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PSX#NYSE">PSX</a>) fell 0.86% ahead of its earnings to be released before the opening bell. Analysts expect it to report quarterly earnings of 23 cents per share on revenue of $32.24 billion.</li>
</ul>
<ul>
<li>Chevron Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVX#NYSE">CVX</a>) was down 0.17% as Wall Street expects it to report earnings of $2.11 per share on revenue of $48.41 billion, before the opening bell.</li>
</ul>
<ul>
<li>Other companies that are slated to report earnings today included Exxon Mobil Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XOM#NYSE">XOM</a>) up 0.6%, Novartis AG (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVS#NYSE">NVS</a>) up 1.49%, Charter Communications Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CHTR#NASDAQ">CHTR</a>) up 2.09%, AbbVie Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABBV#NYSE">ABBV</a>) up 0.99%, WW Grainger Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GWW#NYSE">GWW</a>) up 1.05% and Charter Communications Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CHTR#NASDAQ">CHTR</a>) up 2.09%.</li>
</ul>
<ul>
<li>Nauticus Robotics Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KITT#NASDAQ">KITT</a>) was up 46.15% after announcing a partnership to advance subsea autonomy solutions.</li>
</ul>
<ul>
<li>Cipher Mining Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CIFR#NASDAQ">CIFR</a>) was up 19.57% after the company announced a $50 million investment from Softbank.</li>
</ul>
Commodities, Gold And Global Equity Markets:
Crude oil futures were trading lower in the early New York session by 0.08% to hover around $72.67 per barrel.
The gold spot index was down by 0.08% to $2,791.94 per ounce. The Dollar Index was up 0.42% at 108.246 level.
Asian markets were higher on Friday except South Korea's Kospi index. Australia's ASX 200, Japan's Nikkei 225, South Korea's Kospi, Hong Kong's Hang Seng, and India's S&amp;P BSE Sensex rose. European markets were also higher in trade.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/01/43376448/elon-musks-x-money-to-see-about-600-million-active-monthly-users-via-visa-direct-integration">Elon Musk&#8217;s &#8216;X Money&#8217; To See About 600 Million Active Monthly Users Via Visa Direct Integration: &#8216;Excited To Partner,&#8217; Says CEO</a></li>
</ul>
Photo courtesy: Shutterstock

Analyst Color

Equities

Government

Market Summary

Regulations

Bonds

Broad U.S. Equity ETFs

Futures

Forex

Treasuries

Pre-Market Outlook

Markets

ETFs

General

AAPL

ABBV

CHTR

CIFR

KITT

MSFT

US Stock Futures Climb After Apple Beats Q4 Expectations: Expert Says Tech Stocks Hold Above Key Level Despite DeepSeek Impact

OneMain Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OMF#NYSE">OMF</a>) reported quarterly earnings of $1.16 per share which beat the analyst consensus estimate of $1.15 by 0.87 percent. This is a 16.55 percent decrease over earnings of $1.39 per share from the same period last year. The company reported quarterly sales of $1.01 billion which missed the analyst consensus estimate of $1.04 billion by 3.27 percent. This is a 10.03 percent increase over sales of $917.00 million the same period last year.

Earnings Misses

OneMain Holdings Q4 Adj EPS $1.16 Beats $1.15 Estimate, Sales $1.01B Miss $1.04B Estimate

Autoliv Sees FY25 Organic Growth Of About 2%

In November 2024, a positive opinion was received from the Committee for Medicinal Products for Human Use (CHMP) recommending approval of lecanemab.1 As part of its decision-making process, the European Commission (EC) has asked the CHMP to consider information on the safety of lecanemab that became available after the adoption of the CHMP opinion in November 2024 and whether this may require an update of the opinion, and to consider whether the wording of the risk minimization measures in the opinion is clear enough to ensure correct implementation. These will be discussed at the CHMP meeting in February 2025.
 &nbsp;

BIIB

Biogen And Eisai Reveals Update On Ongoing Regulatory Review Of Marketing Authorization Application For lecanemab As Treatment For Early AD In European Union

Comments

Corix Bioscience

News

Latest news for Corix Bioscience (OTC:CXBS) Stock

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga